文献速递妇科生殖医学

多囊卵巢综合征研究结局的国际核心结局集

Harmonising research outcomes for polycystic ovary syndrome: an international multi-stakeholder core outcome set.
PubMed 文献 · Hum Reprod · 2020-01-01

本研究通过证据合成、改良德尔菲法电子调查和咨询会议,涉及17个国家的71名卫生专业人员和123名患者消费者,制定了多囊卵巢综合征研究的核心结局集,包括3个通用结局和6个专业领域的30个特定结局,旨在改善报告质量和证据合成。

要点

  • 核心结局集含3个通用结局:BMI、生活质量、治疗满意度。
  • 30个特定结局分属代谢、生殖、妊娠、心理、肿瘤和长期结局6领域。
  • 实施该核心结局集可提高PCOS研究报道质量并促进证据合成。

核心结论

  • 确定了PCOS研究的3个通用和30个特定核心结局,覆盖6个专业领域。

研究设计与样本

  • 证据合成与改良德尔菲法电子调查及咨询会议。
  • 共71名卫生专业人员和123名消费者(有PCOS经历的女性及倡导支持组成员)参与,来自17个高、中、低收入国家。

主要发现

  • 最终核心结局集包括3个通用结局:BMI、生活质量、治疗满意度。
  • 30个特定结局:代谢8个、生殖7个、妊娠10个、心理3个、肿瘤1个、长期1个。
  • 代谢结局包括腰围、2型糖尿病、胰岛素抵抗等;生殖结局包括活产妊娠、临床和生化高雄激素血症等;妊娠结局包括活产、流产、死产等;心理结局包括抑郁、焦虑、进食障碍;肿瘤结局为异常子宫内膜增殖;长期结局为子代代谢和发育结局。

临床怎么用

  • 未来PCOS研究应采用此核心结局集,以提高报告质量和证据合成。

局限性

  • 消费者仅通过电子调查参与,未通过焦点小组,限制了对他们选择的理解。
  • 未解决部分核心结局定义和测量工具的变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the key core outcomes to be reported in studies on polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: We identified 3 generic and 30 specific core outcomes in 6 specialist domains: metabolic (8), reproductive (7), pregnancy (10), oncological (1), psychological (1) and long-term outcomes (1). WHAT IS KNOWN ALREADY: Research reporting PCOS is heterogeneous with high variation in outcome selection, definition and quality. STUDY DESIGN, SIZE, DURATION: Evidence synthesis and a modified Delphi method with e-surveys were used as well as a consultation meeting. PARTICIPANTS/MATERIALS, SETTING, METHODS: Overall, 71 health professionals and 123 lay consumers (women with lived experience of PCOS and members of advocacy and peer support groups) from 17 high-, middle- and low-income countries were involved in this analysis. MAIN RESULTS AND THE ROLE OF CHANCE: The final core outcome set included 3 generic outcomes (BMI, quality of life, treatment satisfaction) that are applicable to all studies on women with PCOS and 30 specific outcomes that were categorised into six specialist domains: 8 metabolic outcomes (waist circumference, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypertension, coronary heart disease, lipid profile, venous thromboembolic disease); 7 reproductive outcomes [viable pregnancy (confirmed by ultrasound including singleton, twins and higher multiples), clinical and biochemical hyperandrogenism, menstrual regularity, reproductive hormonal profile, chronic anovulation, ovulation stimulation success including the number of stimulated follicles ≥ 12 mm, incidence and severity of ovarian hyperstimulation syndrome]; 10 pregnancy outcomes (live birth, miscarriage, stillbirth, neonatal mortality, gestational weight gain, gestational diabetes, preterm birth, hypertensive disease in pregnancy, baby birth weight, major congenital abnormalities); 3 psychological outcomes (depression, anxiety, eating disorders); 1 oncological (abnormal endometrial proliferation including atypical endometrial hyperplasia and endometrial cancer); and 1 outcome in the long-term domain (long-term offspring metabolic and developmental outcomes). LIMITATIONS, REASONS FOR CAUTION: We involved lay consumers in all stages of study through e-surveys but not through focus groups, thereby limiting our understanding of their choices. We did not address the variations in the definitions and measurement tools for some of the core outcomes. WIDER IMPLICATIONS OF THE FINDINGS: Implementing this core outcome set in future studies on women with PCOS will improve the quality of reporting and aid evidence synthesis. STUDY FUNDING/COMPETING INTEREST(S): Evidence synthesis was funded through the Australian government, National Health and Medical Research Council (NHMRC) Centre for Research Excellence in PCOS, and H.T. is funded through an NHMRC fellowship. B.H.A. is funded through an NIHR lectureship. All authors have no competing interest to declare.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Al Wattar BH, Teede H, Garad R, et al. Harmonising research outcomes for polycystic ovary syndrome: an international multi-stakeholder core outcome set. Hum Reprod. 2020. PMID: 32020203. doi:10.1093/humrep/dez272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。